CN110128544B - Hybrid peptide with immunoregulation and anti-inflammatory functions and preparation method and application thereof - Google Patents
Hybrid peptide with immunoregulation and anti-inflammatory functions and preparation method and application thereof Download PDFInfo
- Publication number
- CN110128544B CN110128544B CN201910265006.4A CN201910265006A CN110128544B CN 110128544 B CN110128544 B CN 110128544B CN 201910265006 A CN201910265006 A CN 201910265006A CN 110128544 B CN110128544 B CN 110128544B
- Authority
- CN
- China
- Prior art keywords
- ctp
- hybrid peptide
- inflammatory
- polypeptide
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 171
- 230000006870 function Effects 0.000 title claims abstract description 32
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000007365 immunoregulation Effects 0.000 title abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 10
- 241000235058 Komagataella pastoris Species 0.000 claims description 8
- 230000002519 immonomodulatory effect Effects 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 7
- 239000012620 biological material Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 239000003674 animal food additive Substances 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 230000004957 immunoregulator effect Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 28
- 230000004054 inflammatory process Effects 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 18
- 230000036737 immune function Effects 0.000 abstract description 14
- 230000006378 damage Effects 0.000 abstract description 11
- 230000002757 inflammatory effect Effects 0.000 abstract description 10
- 101000859018 Gallus gallus Cathelicidin-2 Proteins 0.000 abstract description 9
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 9
- 108010046075 Thymosin Proteins 0.000 abstract description 7
- 102000007501 Thymosin Human genes 0.000 abstract description 7
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 abstract description 7
- 206010062016 Immunosuppression Diseases 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 6
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000003124 biologic agent Substances 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 74
- 229920001184 polypeptide Polymers 0.000 description 57
- 241000699670 Mus sp. Species 0.000 description 53
- 239000002158 endotoxin Substances 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 36
- 229920006008 lipopolysaccharide Polymers 0.000 description 34
- 238000012360 testing method Methods 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 22
- 229960004397 cyclophosphamide Drugs 0.000 description 22
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 21
- 102400000160 Thymopentin Human genes 0.000 description 19
- 101800001703 Thymopentin Proteins 0.000 description 19
- 229960004517 thymopentin Drugs 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 239000013604 expression vector Substances 0.000 description 16
- 210000002540 macrophage Anatomy 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 238000003259 recombinant expression Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000002457 bidirectional effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241001506991 Komagataella phaffii GS115 Species 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 5
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- 241001052560 Thallis Species 0.000 description 4
- 108060001132 cathelicidin Proteins 0.000 description 4
- 102000014509 cathelicidin Human genes 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- BNYNOWJESJJIOI-XUXIUFHCSA-N Arg-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N BNYNOWJESJJIOI-XUXIUFHCSA-N 0.000 description 3
- UGZUVYDKAYNCII-ULQDDVLXSA-N Arg-Phe-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UGZUVYDKAYNCII-ULQDDVLXSA-N 0.000 description 3
- UGJLILSJKSBVIR-ZFWWWQNUSA-N Arg-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCN=C(N)N)N)C(=O)NCC(O)=O)=CNC2=C1 UGJLILSJKSBVIR-ZFWWWQNUSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- VPKBCVUDBNINAH-GARJFASQSA-N Glu-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O VPKBCVUDBNINAH-GARJFASQSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- CLBGMWIYPYAZPR-AVGNSLFASA-N Lys-Arg-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O CLBGMWIYPYAZPR-AVGNSLFASA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108010085059 glutamyl-arginyl-proline Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101150058391 CTP gene Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000000898 Thymopoietin Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 108010001055 thymocartin Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101000753683 Bos taurus Thymopoietin-2 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 101710178510 Defensin-2 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 1
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 1
- YOZCKMXHBYKOMQ-IHRRRGAJSA-N Leu-Arg-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOZCKMXHBYKOMQ-IHRRRGAJSA-N 0.000 description 1
- 102000018671 Lymphocyte Antigen 96 Human genes 0.000 description 1
- 108010066789 Lymphocyte Antigen 96 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 102400000159 Thymopoietin Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- HQJOVVWAPQPYDS-ZFWWWQNUSA-N Trp-Gly-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQJOVVWAPQPYDS-ZFWWWQNUSA-N 0.000 description 1
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 1
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108010007004 cathelin Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Abstract
The invention relates to the technical field of genetic engineering and biological agents, in particular to a hybrid peptide with immunoregulation and anti-inflammatory functions, a preparation method and application thereof. The invention provides an immune anti-inflammatory hybrid peptide CTP which is obtained by hybridizing, optimizing and screening an antibacterial peptide CATH-2 and a thymosin TP5, wherein the amino acid sequence is shown as SEQ ID NO. 1. The hybrid peptide CTP has higher two-way immunoregulation activity, can enhance the immune function of an organism in a normal or immunosuppressive state, and protects the damage of immunosuppression to the organism; under the inflammatory state, CTP can also inhibit the inflammatory reaction of the organism and relieve the injury of the inflammatory reaction to tissues, has the advantages of low cytotoxicity, high safety, simple preparation method, low cost and the like, can be used as an ideal immune anti-inflammatory regulator, and has good application potential and value.
Description
Technical Field
The invention relates to the field of genetic engineering and biological agents, in particular to a hybrid peptide with immunoregulation and anti-inflammatory functions, a preparation method and application thereof.
Background
In the case of young age, weakness, diseases, stress, pathogenic infection, etc., animals or humans often cause a decrease in immunity, and further, secondary infection (mixed infection of bacteria or viruses) occurs, causing inflammatory reaction (red, heat, swelling, pain, etc.). At present, for the treatment of infection and inflammation, the traditional and commonly used prevention and treatment strategy is to use antibiotics and hormone anti-inflammatory drugs (such as hydrocortisone, dexamethasone and the like), although the antibiotics and hormone anti-inflammatory drugs can effectively control infectious inflammation and non-infectious inflammation, the continuous use can cause various side effects: such as serious disorders of water and salt metabolism and sugar, fat and protein metabolism, and cause deterioration of adrenal cortex function, complications of digestive system or aggravated infection. In addition, antibiotic health promoting growth promoter is widely used in animal husbandry. There are significant problems with the use of antibiotic or hormonal anti-inflammatory drugs in the treatment of infection and inflammation: antibiotics can reduce or kill pathogenic bacteria, but cannot improve the immune function of the body, on the contrary, the bacteria killed by the antibiotics can produce endotoxin or exotoxin, further aggravate inflammatory reaction and even cause systemic inflammatory response syndrome (Botwinski,2001), which causes animals to have fever, anorexia, excessive consumption of energy in vivo, decomposition of body tissues, reduction of immunity and productivity, and death of livestock and poultry (Botwinski, 2001; nneZir, 1999). In recent years, a lot of studies have shown that many antibiotics, while killing bacteria, can also promote the release of endotoxin, i.e. Lipopolysaccharide (LPS), from the bacterial cell membrane (Holzheimer, 2001; Hurley,1995), which in turn causes the LPS to accumulate in a large amount and cause inflammatory reaction. Endotoxin LPS is usually produced by cell disintegration of gram-negative bacteria such as pathogenic Escherichia coli, Salmonella, Brucella, Proteus, swine influenza and Haemophilus parasuis, and can induce release of various proinflammatory cytokines such as TNF-alpha, interleukin 6(IL-6) and IL-1 beta; and simultaneously, a large amount of free radicals are induced to be generated to cause oxidative damage, so that the immunity is reduced. Thus, reduction or elimination of endotoxin, LPS, can reduce or eliminate the inflammatory response in a patient animal or human. In summary, the existing antibiotic anti-infection and glucocorticoid anti-inflammatory drugs have obvious defects and are not suitable for continuous use. Therefore, the development of a novel, safe and environment-friendly active peptide with no side effect and simultaneously having the functions of immunoregulation, endotoxin digestion and anti-inflammation has important practical significance and huge application prospect for human or animal breeding industry, and is a new breakthrough and new concept of anti-infection strategy.
The immune system can protect the body from being invaded by external microorganisms through the immune defense function, and can remove aging and canceration cells in the body in time. On one hand, when the immune function is lower than the normal level, the organism is very easy to be infected and induce the generation of malignant tumor, and the like, thereby causing the aggravation of the disease of the patient to be difficult to treat; on the other hand, however, when the immune response is excessive, the immune response may cause a strong inflammatory response in animals or humans, which may result in body damage and dysfunction of various physiological systems, which may further affect the normal metabolic processes of the body, and even endanger life of the serious people. It follows that anti-inflammatory and immune are two aspects of immune system function, closely related, inseparable, and sometimes even overlapping. Therefore, in the traditional medicine field, the complete separation of anti-inflammatory drugs and immune-enhancing drugs is not in accordance with the actual needs of the body or the interaction relationship between anti-inflammatory and immune, and greatly increases the complexity and antagonism of clinical drug selection. In view of the above, it is important to develop safe and efficient preparations or drugs having a bidirectional immunoregulatory function to improve the immune function of animals and humans.
Cathelicidins are one of the largest families of antimicrobial peptides currently known and have been reported in vertebrates, including mammals, birds, reptiles, amphibians and fish. The Cathelicidin is composed of an N-terminal signal peptide region, a middle conserved cathelin structural domain and a C-terminal highly specific mature peptide region and plays an extremely important role in an animal innate immune system. In addition to broad-spectrum antibacterial activity, Cathelicidin also has excellent anti-inflammatory functions, such as chemotaxis of various immune cells, induction of mast cell degranulation and histamine release, regulation of macrophage transcription, promotion of wound healing, induction of apoptosis of variant cell lines, lymphocyte activation and the like. Poultry defensin 2(CATH-2) is an important representative polypeptide of the Cathelicidin family.
The human studies on immunologically active peptides began in 1981 when Jolles et al first isolated an immunologically active peptide fragment from human milk protein hydrolysates. After that, many studies on immunologically active peptides have been conducted by scientists, and among them, studies on thymosin have been reported and conducted more deeply. Thymopentin (TP5), the active center of thymopoietin II, has biological activity similar to that of thymopoietin, can regulate unbalanced immune function bidirectionally, induce cell differentiation, promote lymphocyte subpopulation development and activation, and is an important immunomodulator.
With the continuous and deep research on the structure, function and action mechanism of anti-inflammatory peptides and immune enhancing peptides, researchers have tried to design bidirectional immune modulating peptides with higher safety and stronger regulatory activity by using protein engineering methods. Research has reported that by hybridizing different types of polypeptides, a novel multifunctional polypeptide is obtained or different immunologically active peptides and anti-inflammatory peptides are hybridized to obtain a novel anti-inflammatory and modulatory agent.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide a hybrid peptide with immunoregulation and anti-inflammatory functions, and a preparation method and application thereof.
In order to achieve the purpose, the technical scheme of the invention is as follows: on the basis of carrying out a great deal of research on the sequences, structures and the relationship between the sequence structures and functions of the polypeptide CATH-2 and the thymosin TP5, the invention utilizes a protein molecule design technology to carry out hybrid optimization of the polypeptide CATH-2 and the thymosin TP5, and finally obtains a novel immune anti-inflammatory hybrid peptide (IAIHP) named as CTP by screening and sequence optimization of the hybrid peptide, wherein the amino acid sequence of the hybrid peptide is shown as SEQ ID NO. 1. The hybrid peptide CTP has the functions of two maternal peptides, namely has bidirectional immunoregulation function: under normal or immune suppression state, the immune function of the organism can be improved; in the inflammatory state, CTP also inhibits the inflammatory response of the body and is more immunomodulatory and anti-inflammatory than the corresponding activities of the maternal peptides CATH-2 and TP 5.
Firstly, the invention provides a hybrid peptide with immunoregulation and anti-inflammatory functions, wherein the amino acid sequence of the hybrid peptide is shown as SEQ ID NO.1 or the amino acid sequence of the polypeptide with the same function obtained by replacing, deleting or inserting one or more amino acids in the amino acid sequence shown as SEQ ID NO. 1.
The derivative polypeptide of the hybrid peptide CTP with the same function obtained by modifying on the basis of the amino acid sequence shown as SEQ ID NO.1 comprises but is not limited to the following polypeptides:
(1) a polypeptide obtained by adding a protein tag sequence to the C-terminus or N-terminus of the amino acid sequence shown in SEQ ID No.1, for example: polypeptide obtained by adding His label containing 6 His residues at C end or N end of amino acid sequence shown as SEQ ID NO. 1; or polypeptide obtained by adding GST or C-Myc label to C terminal or N terminal of amino acid sequence shown in SEQ ID NO. 1;
it will be understood by those skilled in the art that the addition of tag sequences at both ends of the polypeptide for the purpose of easy purification, polypeptide labeling, etc. is a routine technical means in the art and does not affect the inherent functions and activities of the polypeptide itself, and therefore, the above-mentioned CTP derivatives obtained by adding tag sequences at both ends of the hybrid peptide CTP as shown in SEQ ID No.1 are also within the scope of the present invention.
(2) Polypeptides obtained by conservative amino acid substitution of one or more amino acid sequences in the amino acid sequence shown in SEQ ID No.1, such as: the substitution of Leu at position 6 to Ile does not have much effect on the function of the polypeptide.
The derivative polypeptide of the hybrid peptide with the same function obtained by modifying on the basis of the sequence of the hybrid peptide shown in SEQ ID NO.1 still belongs to the protection scope of the patent.
The present invention also provides a gene encoding the hybrid peptide having immunoregulatory and anti-inflammatory functions.
Given the amino acid sequence of a hybrid peptide CTP, one skilled in the art can design a gene encoding a hybrid peptide CTP having a different nucleotide sequence according to the requirement for polypeptide expression based on the principle of codon degeneracy and codon usage bias of different species.
As an embodiment of the invention, the nucleotide sequence of the gene is shown as SEQ ID NO. 6. The gene shown as SEQ ID NO.6 is a heterozygous peptide CTP coding gene designed according to the codon preference of pichia pastoris.
The gene which is obtained by modifying the coding sequence shown as SEQ ID NO.6 and codes CTP or derivative peptide with the same function as CTP still belongs to the protection scope of the patent.
Further, the present invention also provides a biomaterial containing the gene encoding the hybrid peptide, which comprises a recombinant DNA, an expression cassette, a transposon, a plasmid vector, a phage vector, a viral vector or a host cell.
The host cell comprises an animal cell, a plant cell or a cell line and a microbial cell.
Further, the present invention provides a method for preparing the hybrid peptide, comprising: introducing a gene encoding the hybrid peptide into a host cell and expressing the hybrid peptide.
Preferably, the preparation method comprises the following steps: connecting the encoding gene of the hybrid peptide CTP with an expression vector to construct a recombinant expression vector, and introducing the recombinant expression vector into a host cell by a transgenic method to obtain the host cell introduced with the CTP encoding gene.
The transgenic method includes heat stress transformation, electric transformation, transfection and the like.
The host cell includes but is not limited to animal and plant cells and microbial cells.
Preferably, the host cell is yeast, more preferably pichia pastoris.
When pichia is adopted as a host cell, the encoding gene with a sequence optimized by pichia codon preference as shown in SEQ ID NO.6 is adopted to express the hybrid peptide, so that the expression quantity is better.
As an embodiment of the invention, the preparation of the hybrid peptide takes pichia pastoris as a host, takes an expression vector pPICZ alpha A as a vector, and expresses the hybrid peptide through methanol induction, and the preparation method specifically comprises the following steps:
(1) connecting the coding gene of the hybrid peptide CTP to an expression vector pPICZ alpha A to construct a recombinant expression vector;
(2) transforming the recombinant expression vector into pichia pastoris GS115 to construct recombinant engineering bacteria introduced with heterozygous peptide CTP coding genes;
(3) culturing the recombinant engineering bacteria, and adding methanol to induce the expression of the heterozygosis peptide CTP;
(4) collecting culture liquid supernatant, and purifying to obtain the hybrid peptide CTP.
In-vivo and in-vitro tests prove that the hybrid peptide CTP can improve the immunocompetence of an organism in normal and immunodeficiency states, improve the expression quantity of cell factors, promote the growth of a mouse and relieve the damage of immunodeficiency to the spleen and the thymus of the mouse; in addition, in the inflammatory reaction process, the inflammatory reaction induced by LPS can be inhibited, the expression level of cell factors is reduced, the damage of the inflammatory state to the weight and the intestinal tract of a mouse is relieved, and the immune anti-inflammatory two-way regulation effect is good.
Based on the above functions, the present invention provides the use of the hybrid peptide or the hybrid peptide prepared by the preparation method, or the gene encoding the hybrid peptide or the biomaterial containing the gene encoding the hybrid peptide in the preparation of an immunomodulatory agent.
Preferably, the immunomodulatory agent is an immunopotentiator.
The invention also provides the application of the hybrid peptide or the hybrid peptide prepared by the preparation method or the coding gene of the hybrid peptide or the biological material containing the coding gene of the hybrid peptide in preparing an anti-inflammatory preparation.
The preparation provided by the invention comprises medicines, health products and food or feed additives.
The immunopotentiator can be used for preventing and treating various immunosuppression including body immunosuppression caused by Cyclophosphamide (CY).
The anti-inflammatory agent can be used for preventing and treating various inflammations including inflammatory reaction induced by LPS.
The invention also provides a product comprising said hybrid peptide or a hybrid peptide produced by said method.
The product is any one selected from medicines, health products and food or feed additives.
As an embodiment of the present invention, the present invention provides a pharmaceutical composition comprising the hybrid peptide or the hybrid peptide prepared by the method for preparing the hybrid peptide.
The medicine composition may have the hybrid peptide as the effective component or the hybrid peptide compounded with other active components to constitute the effective component of medicine composition.
Preferably, the pharmaceutical composition further comprises a carrier or an auxiliary material acceptable in the pharmaceutical field.
The invention has the beneficial effects that:
the invention obtains the immune anti-inflammatory hybrid peptide CTP by hybridizing the antibacterial peptide CATH-2 and the thymosin TP5 for the first time and optimizing and screening, wherein the polypeptide CTP has the functions of two maternal peptides, namely has the function of bidirectional immune regulation, and has stronger immune regulation activity and anti-inflammatory activity compared with the corresponding activities of the maternal peptides CATH-2 and TP 5: under the normal or immune suppression state, the immune function of the organism can be obviously improved, and the damage of the immune suppression to the organism can be protected; under the inflammatory state, CTP can also inhibit the inflammatory reaction of the organism and relieve the damage of the inflammatory reaction to tissues; meanwhile, CTP has the advantages of low cytotoxicity, high safety, simple preparation method and low cost, can be used as an ideal immunomodulator and an anti-inflammatory agent, is widely applied to the fields of medicine, food, health care, feed, nutrition and the like of human and animals, and has great application value.
The preparation method of the hybrid peptide provided by the invention can realize the large-scale and high-efficiency preparation of the hybrid peptide CTP, and the prepared hybrid peptide CTP has the bidirectional immunoregulation and anti-inflammatory activity and has no obvious toxic or side effect.
Drawings
FIG. 1 is a molecular docking diagram of a candidate hybrid peptide in example 1 of the present invention, wherein A is a molecular docking 3D simulation diagram of the hybrid peptide, and B is the energy absorbed or released by the hybrid peptide during the molecular docking process (positive values represent the absorbed energy, and negative values represent the released energy).
FIG. 2 is a flow chart showing the construction of recombinant expression vector pPICZ α A-CTP in example 1 of the present invention.
FIG. 3 shows the results of gel electrophoresis in PCR identification of the recombinant expression vector pPICZ α A-CTP in example 1 of the present invention, wherein M is a DNA molecular weight standard; lanes 1-5 are fragments of interest comprising the gene encoding the polypeptide CTP.
FIG. 4 shows the results of electrophoresis and mass spectrometry of polypeptide CTP expressed by Pichia pastoris engineering bacteria purified in example 1, wherein A is the result of SDS-PAGE electrophoresis, and Marker is the protein molecular weight standard; lane 1-2 shows the band of CTP, a target protein purified from the supernatant of 120h fermentation induced with methanol; b is a mass spectrum detection result diagram of the purified polypeptide CTP.
FIG. 5 is a graph showing the effect of hybrid peptide CTP and its parent peptide on cell survival rate of mouse macrophage cells in example 2 of the present invention.
FIG. 6 shows the effect of the polypeptide of example 3 on the cytokine expression level of mouse macrophage RAW 264.7; wherein A is the expression level of TNF-alpha; b is the expression level of IFN-gamma; control represents the normal group, LPS represents the model group of LPS-induced inflammation, CATH2 represents test group 1 (normal condition with addition of CATH2 treatment), TP5 represents test group 2 (normal condition with addition of TP5 treatment), CTP represents test group 3 (normal condition with addition of CTP treatment), CATH2+ LPS represents test group 4 (addition of CATH2 treatment followed by induction of inflammation model with LPS), TP5+ LPS represents test group 5 (addition of TP5 treatment followed by induction of inflammation model with LPS), CTP + LPS represents test group 6 (addition of CTP treatment followed by induction of inflammation model with LPS); represents that the two are compared with a significant difference (p <0.5), and represents that the two are compared with a very significant difference (p < 0.01).
FIG. 7 is the immunomodulatory effect of the polypeptide CTP on cyclophosphamide induced immunosuppression in mice in example 4 of the present invention; wherein A is the influence of CTP on the body weight of an immunosuppressed mouse; b is the influence of CTP immunosuppression on mouse spleen; c is the influence of CTP on the thymus of an immunosuppressed mouse; d is the influence of CTP on the phagocytic activity of mouse macrophages; e is the influence of CTP on the release amount of mouse cytokine IFN-gamma; f is the influence of CTP on the release amount of mouse cytokine IL-6; control represents a blank group, CY represents a model group, and CTP + CY represents a test group; indicates significant difference from blank control group (p <0.5), and # indicates significant difference from model group (p < 0.5).
FIG. 8 is the inhibitory effect of polypeptide CTP on mouse inflammatory response in example 5 of the present invention; wherein A is the influence of CTP on the body weight of a mouse; b is the influence of the intestinal length of the CTP mouse; c is the influence of CTP on the integrity of jejunum tissues of the mice; d is the influence of CTP on the release amount of mouse cytokine IFN-gamma; e is the influence of CTP on the release amount of mouse cytokine IL-6; control represents blank group, LPS represents model group, CTP + LPS represents test group; indicates significant difference from blank control group (p <0.5), and # indicates significant difference from model group (p < 0.5).
Detailed Description
Preferred embodiments of the present invention will be described in detail with reference to the following examples. It is to be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the present invention. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the spirit and scope of this invention.
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available, unless otherwise specified, wherein E.coli competent cell Top 10, Pichia pastoris GS115 and expression vector pPICZ. alpha.A were purchased from Invitrogen corporation.
EXAMPLE 1 preparation of the immune anti-inflammatory hybrid peptide CTP
1. Obtaining hybrid peptide sequences
Through researching the sequences, structures and the relation between the sequence structures and functions of the polypeptide CATH-2 (the sequence is shown as SEQ ID NO. 2) and the thymosin TP5 (the sequence is shown as SEQ ID NO. 3), the polypeptide CATH-2 and the thymosin TP5 are hybridized by utilizing a protein molecule design technology, and a plurality of candidate hybrid peptides are obtained. This example illustrates the screening process of the immune anti-inflammatory hybrid peptide CTP by taking candidate hybrid peptide CTP (shown in SEQ ID NO. 1), TP5-CATH2 (shown in SEQ ID NO. 4) and CATH2-TP 5' (shown in SEQ ID NO. 5) as examples.
The anti-inflammatory immune effect of each candidate hybrid peptide is preliminarily predicted by molecular docking of each candidate hybrid peptide with the MD-2 protein according to the grading condition of molecular docking by utilizing the characteristics of myeloid differentiation protein-2 (MD-2) (namely, the MD-2 is combined with TLR4 to endow TLR4 with the reactivity to various ligands including LPS, and the MD-2 can promote the expression of TLR4 and TLR2 and is closely related to the distribution of TLR4 in cells, so that the MD-2 is not only an auxiliary molecule of TLR4, but also a regulatory molecule in natural immunity and has wide biological functions in pathophysiological processes of infection, inflammation, immunity and the like).
The molecular docking results of the candidate hybrid peptides CTP, TP5-CATH2 and CATH2-TP 5' are shown in A of figure 1, the energy change conditions of the three candidate hybrid peptides are shown in B of figure 1, and the three candidate hybrid peptides can release energy when being combined with MD-2, but the CTP releases the energy most, which indicates that the combination of the three candidate hybrid peptides with MD-2 is more stable and has better anti-inflammatory and immune activities. And (3) integrating other screening experiment results, and finally screening to obtain the hybrid peptide CTP, wherein the amino acid sequence of the hybrid peptide CTP is shown in SEQ ID No. 1.
2. Construction of recombinant expression vectors
Designing and synthesizing a coding gene (the sequence is shown as SEQ ID NO. 6) of the polypeptide CTP according to the amino acid sequence of the hybrid peptide CTP (polypeptide CTP for short) and the codon preference of pichia pastoris, adding a His label at the C end of the polypeptide CTP on the basis of the CTP coding gene sequence shown as SEQ ID NO.6, connecting the CTP coding gene sequence with the His label (shown as SEQ ID NO. 7) with an expression vector pPICZ alpha A, transforming the expression vector pPICZ alpha A-CTP to escherichia coli Top 10 competent cells, and constructing a recombinant expression vector pPICZ alpha A-CTP, wherein the construction process of the vector is shown as figure 2.
Extracting plasmids according to the operation method of a small plasmid extraction kit of Tiangen Biochemical technology (Beijing) Ltd, performing PCR amplification on a CTP gene by taking the extracted plasmids as a template, wherein an upstream primer is 5'-CCAGATGGGGTAGATTCTT-3'; a downstream primer: 5'-GTAACGTCCTTTCTCTTTG-3' are provided. The amplification product was subjected to agarose gel electrophoresis, observed under an ultraviolet lamp, and the conversion result was identified, as shown in fig. 3, showing that a band (96bp) of the CTP gene was present in the amplification product. Sequencing the recombinant plasmid further identified whether the insertion of the desired fragment was correct and the fidelity of the inserted fragment was checked. Sequencing proves that the recombinant expression vector pPICZ alpha A-CTP is successfully constructed.
3. Preparation of Pichia competent cells
Inoculating single colony of Pichia pastoris GS115 into 3-5ml YPD (2% tryptone, 2% glucose, 1% yeast powder, pH 7.0) liquid culture medium, performing shake culture at 30 deg.C for about 12 hr, inoculating into 100ml YPD liquid culture medium at volume ratio of 1:100-1:50, performing shake culture at 30 deg.C to OD600The culture was stopped at about 1.3-1.5. The culture was transferred to a centrifuge tube, left on ice for 10 minutes, and then centrifuged at 1500 Xg for 5 minutes at 4 ℃ to collect the cells. The cells were gently suspended in precooled sterile water, left on ice for 15-30 minutes, and then centrifuged at 1500 Xg for 5 minutes at 4 ℃. The supernatant was discarded, 10ml of a pre-cooled sterile sorbitol solution (1M) was added, and the cells were resuspended to obtain a competent cell suspension. 200. mu.l of each tube was dispensed into Pichia pastoris GS115 competent cells for use immediately or stored at-70 ℃.
4. Construction of Pichia pastoris engineering bacteria for expressing heterozygosis peptide CTP
Converting the recombinant expression vector pPICZ alpha A-CTP constructed in the step 3 into a Pichia pastoris GS115 strain, wherein the specific method is as follows:
mixing 5-10 mu g of linearized recombinant plasmid pPICZ alpha A-CTP with 200 mu l of competent cells of activated Pichia pastoris GS115, transferring the mixture into an electric rotating cup, carrying out ice bath for 5-30min, carrying out electric rotation for a plurality of seconds after ice bath (oscillation is avoided in the electric rotation process), then quickly placing the mixed solution on ice, quickly adding 1ml of ice-bath 1M sorbitol solution, suspending and uniformly mixing thalli, transferring the thalli into a 1.5ml EP tube, placing the thalli on ice, then adding 2ml of YPD liquid culture medium, and culturing for 3h at 30 ℃ to enable the strains to recover and form resistance. After the recombinant bacteria became resistant, 200. mu.l of the culture broth was spread on YPDS plates containing 100. mu.g/ml kanamycin, and the plates were inverted and cultured overnight at 30 ℃. And (3) selecting a single colony growing on the YPDS plate, inoculating the single colony in a YPD liquid culture medium containing 100 mu g/ml kanamycin for overnight culture, extracting plasmids by adopting a small-plasmid extraction medium-volume kit, and identifying a positive transformant through PCR verification to obtain the pichia pastoris engineering bacteria expressing the heterozygous peptide CTP.
5. Inducible expression of the hybrid peptide CTP
Selecting Pichia engineering bacteria expressing hybrid peptide CTP, inoculating into BMGY culture medium containing 100 ug/ml kanamycin, shake culturing at 30 deg.C and 180-600When the number is 2-6, the thalli are collected by low-speed centrifugation; resuspending the cells to OD in BMMY Medium600The culture was carried out at 30 ℃ and 200rpm with shaking at 1. During the shaking culture process, methanol is added every 24h to a final concentration of 5% for the induced expression of polypeptide CTP. 2ml of bacterial liquid is taken when methanol induction is carried out for 120h, centrifugation is carried out for 5min at 12000rpm, and supernatant is collected and stored at minus 20 ℃. And (3) carrying out Tricine-SDS-PAGE electrophoresis detection on the collected culture supernatant, wherein an electrophoresis result shows that the culture supernatant contains polypeptide CTP, the polypeptide CTP is successfully expressed, and the expression quantity of the polypeptide CTP can reach about 50mg/L through determination.
6. Purification of hybrid peptide CTP
When synthesizing CTP coding gene, histidine tag (6 × His) is added at C-terminal, so polypeptide CTP can be combined with Ni in Ni-NTA Sepharose chromatographic column2+And (3) combining, eluting the fermentation supernatant by using imidazole eluents with different concentrations, and collecting an elution peak sample, so that the separation and purification of the polypeptide CTP can be realized. Method for purifying Ni-NTA Sepharose chromatographic column by polypeptide CTP (computer to plate) by referring to using instruction of chromatographic column productCollecting samples of each elution peak, detecting the purification effect through Tricine-SDS-PAGE electrophoresis, wherein the molecular weight of CTP is 2.7KDa, and the result is shown in A of figure 4, which shows that the polypeptide CTP with higher purity is obtained through purification; the mass spectrometric detection result of the purified CTP is shown in fig. 4B, which indicates that the molecular weight of the purified polypeptide is consistent with the theoretical molecular weight of CTP.
Example 2 Effect of hybrid peptide CTP on mouse macrophage cell survival
Taking macrophage RAW264.7 in logarithmic growth phase to inoculate in a 96-well plate, wherein the initial cell culture density is 1 multiplied by 104one/mL, 100. mu.L per well, 5% CO at 37 ℃2After culturing overnight under the condition of (1), adding a series of concentration gradients of CTP, CATH2 and TP5(0-100 mu g/mL), and after culturing for 24 hours, detecting the influence of the hybrid peptide CTP and the maternal peptides CATH2 and TP5 on the survival rate of mouse macrophages by using a CCK8 method. The result is shown in figure 5, the cytotoxicity of the polypeptide CTP is obviously reduced compared with that of the parent peptide CATH2, and the polypeptide CTP has no cytotoxicity at the concentration of 10 mug/mL, thereby being beneficial to subsequent research and application.
Example 3 immunomodulatory Activity of hybrid peptide CTP in mouse macrophages
Diluting the hybrid peptide CTP and the parent peptide CATH2 and TP5 with DMEM medium, preparing a polypeptide solution with the concentration of 10 mu g/mL, and detecting the influence of the CTP and the parent peptide CATH2 and TP5 on the secretion of cytokines such as TNF-alpha, IFN-gamma and the like of mouse macrophage RAW264.7 under normal state and LPS-induced inflammation state. Respectively setting a normal group (Control), a model group (LPS), a test group 1(CATH2), a test group 2(TP5), a test group 3(CTP), a test group 4(CATH2+ LPS) and a test group 5(TP5+ LPS), wherein the normal group is not subjected to any treatment; test groups 1, 2 and 3 respectively add CATH2, TP5 or CTP solution with the final concentration of 10 mug/mL after overnight culture of cells; test groups 4, 5, and 6 were added with a final concentration of 10. mu.g/mL CATH2, TP5, or CTP solution after overnight cell culture, and one hour later, the model group and test groups 4, 5, and 6 were added with a final concentration of 100ng/mL LPS solution, respectively. The ELISA method is adopted to detect the cytokines TNF-alpha and IFN-gamma, the result is shown in figure 6, under the normal state, the hybrid peptide CTP can obviously improve the expression level of the mouse macrophage cytokines TNF-alpha (A in figure 6) and IFN-gamma (B in figure 6), and the expression level of the macrophage cytokines TNF-alpha and IFN-gamma in the CTP group is obviously higher than that in the CATH2 group and the TP5 group; but at the same time, when the cells are in an inflammatory state induced by LPS, CTP can obviously inhibit the expression of TNF-alpha (A of figure 6) and IFN-gamma (B of figure 6) cytokines, and the inhibition effect is better than that of the maternal peptides CATH2 and TP 5. Therefore, the polypeptide CTP has the two-way immunoregulation function, can enhance the immunocompetence of cells under the normal state and inhibit the inflammatory reaction of the cells under the inflammatory state, and has the immune anti-inflammatory effect superior to the maternal peptides CATH2 and TP 5.
EXAMPLE 4 immunomodulatory Effect of hybrid peptide CTP on immunosuppressive mice
In the embodiment, the animal experiment is carried out by adopting C57BL/6 male mice (with the weight of 20-22 g, purchased from Beijing Wintoli laboratory animal technology Co., Ltd.), the whole experiment process refers to the guiding principle of European laboratory animal ethics committee (86/609/EEC), and the approval of the Chinese agriculture university laboratory animal ethics committee is obtained. The animal feeding environment is clean, the environment temperature is 22 +/-2 ℃, the humidity is 50% -55%, and the illumination is 8: 00-20: 00. The mice are raised in 6-8 cages and can freely eat and drink water.
1. Effect of polypeptide CTP on body weight and immune organ weight of immunosuppressed mice
36 healthy male mice were randomly divided into 3 groups of 12 mice each. Divide into blank group (Control): physiological saline; model group (CY): cyclophosphamide CY (100mg/kg) was injected; test group (CTP + CY): CTP (10mg/kg) and cyclophosphamide CY (100mg/kg) were injected.
Mice in the test group were administered polypeptide CTP (administered at a dose of 10mg/kg) by intraperitoneal injection for 14 days, once a day, and the blank group and the model group were administered with corresponding volumes of physiological saline. From the 8 th day of administration, mice in the model group and the test group were subjected to intraperitoneal injection of cyclophosphamide at 100mg/kg, and mice in the blank group were administered with the same amount of physiological saline, and were injected every other day for 4 times to prepare animal models with low immune function. After the last administration, the mice were sacrificed by dislocation of cervical vertebrae, the body weights of the mice were recorded, the spleen and the thymus were taken and weighed as wet weights, respectively, and the spleen index and the thymus index of the mice were calculated (spleen index ═ mouse spleen weight/body weight, thymus index ═ mouse thymus weight/body weight). The results are shown in A, B and C of fig. 7, and the results show that the body weight, spleen index and thymus index of the model group mice are all significantly reduced compared with those of the blank group, which indicates that cyclophosphamide can inhibit the growth of the mice, reduce the immune organ index and inhibit the immunity; the body weight, spleen index and thymus index of the mice in the test group are all restored to the normal level of the blank group, which shows that the polypeptide CTP can promote the growth of the mice with low immune function and has protective effect on the immune organs of the mice with low immune function.
2. Effect of polypeptide CTP on macrophage phagocytic Activity in immunosuppressed mice
36 healthy male mice were randomly divided into 3 groups of 12 mice each. The method is divided into a blank group: physiological saline; model group: cyclophosphamide CY (100mg/kg) was injected; test groups: CTP (10mg/kg) and cyclophosphamide CY (100mg/kg) were injected.
The administration modes of the blank group, the model group and the test group are the same as that in the 1, 24 hours after the last administration, the mice are killed after blood sampling, the mice are respectively soaked in 75% ethanol for 5-10s, 4mL of RPMI1640 added with heparin is injected into the abdominal cavity, the eluate is centrifuged, the supernatant is discarded, and the abdominal cavity macrophage is obtained by separation. 0.5mL of 10% fetal bovine serum-containing RPMI1640 was added to the pellet and resuspended, and the cell concentration was adjusted to 5X 106one/mL, seeded in 96-well plates at 37 ℃ with 5% CO2Culturing for 3h in the environment, discarding the supernatant, adding neutral red physiological saline solution, cracking the cells after 10min, and detecting the absorbance at the wavelength of 540 nm. The experimental results are shown in fig. 7D, and the results show that compared with the blank group, the phagocytic rate of the neutral erythrocytes of the model group is significantly reduced, cyclophosphamide can inhibit the phagocytic activity of macrophages of mice, and CTP can restore the phagocytic activity of macrophages of mice with low immune function, thereby enhancing the innate immunity of the mice with low immune function.
(3) Effect of polypeptide CTP on cytokine release amount of immunosuppressive mice
36 healthy male mice were randomly divided into 3 groups of 12 mice each. The method is divided into a blank group: physiological saline; model group: cyclophosphamide CY (100mg/kg) was injected; test groups: CTP (10mg/kg) and cyclophosphamide CY (100mg/kg) were injected.
The administration modes of the blank group, the model group and the test group are the same as those in the above 1, and 24 hours after the last administration, blood is taken from eyeballs, serum is separated, and the contents of cytokines (IFN-gamma, IL-6) in the mouse serum are detected by an ELISA method. The experimental results are shown in E, F of fig. 7, and the results show that the content of the cytokines (IFN-gamma and IL-6) in the mice of the model group is obviously reduced compared with that of the blank group; the administration of the polypeptide CTP can obviously improve the content of cell factors (IFN-gamma and IL-6) in the serum of an immunosuppressed mouse, thereby improving the immunocompetence of the mouse with low immune function.
Example 5 anti-inflammatory Effect of hybrid peptide CTP on mice with inflammatory states
In the embodiment, the animal experiment is carried out by adopting C57BL/6 male mice (with the weight of 20-22 g, purchased from Beijing Wintoli laboratory animal technology Co., Ltd.), the whole experiment process refers to the guiding principle of European laboratory animal ethics committee (86/609/EEC), and the approval of the Chinese agriculture university laboratory animal ethics committee is obtained. The animal feeding environment is clean, the environment temperature is 22 +/-2 ℃, the humidity is 50% -55%, and the illumination is 8: 00-20: 00. The mice are raised in 6-8 cages and can be fed with food and water.
1. Effect of polypeptide CTP on body weight and intestinal tract of mice in inflammatory state
36 healthy male mice were randomly divided into 3 groups of 12 mice each. Divide into blank group (Control): physiological saline; model group (LPS): LPS (10 mg/kg); test group (CTP + LPS): CTP (10mg/kg), LPS (10 mg/kg).
Mice in the test group were administered polypeptide CTP (administration dose of 10mg/kg) by intraperitoneal injection for 7 days, and mice in the blank group and the model group were administered physiological saline in a volume corresponding to the administration dose once a day. After the last administration for 1H, mice in the model group and the test group were subjected to intraperitoneal injection of LPS (10mg/kg), the blank group was administered with an equal amount of physiological saline, the mice were sacrificed by cervical dislocation after 6H, the weight and intestinal length of the mice were recorded, and the jejunum of the mice was taken for H & E staining and section observation. The experimental results are shown in A, B and C of fig. 8, and the results show that the weight and the intestinal length of the model group mice are both significantly reduced compared with those of the blank group, and the intestinal villus morphology of the model group is found to be damaged through section observation, and meanwhile, the submucosa has obvious edema phenomenon, which indicates that the inflammatory reaction induced by LPS can cause the weight reduction, the intestinal atrophy and the injury of the mice; the body weight and intestinal length of the mice in the test group are restored to the normal level of the blank group, the intestinal villus form and the edema phenomenon are obviously improved, and the polypeptide CTP can protect the damage of inflammatory reaction induced by LPS to the body weight and the intestinal tract of the mice.
2. Effect of polypeptide CTP on cytokine expression level of mice in inflammatory states
36 healthy male mice were randomly divided into 3 groups of 12 mice each. The method is divided into a blank group: physiological saline; model group: LPS (10 mg/kg); test groups: CTP (10mg/kg), LPS (10 mg/kg).
The administration modes of the blank group, the model group and the test group are the same as that in the 1, LPS (10mg/kg) is injected into the abdominal cavity of the mice of the model group and the test group after 1 hour of the last administration, the blank group is given with the same amount of physiological saline, blood is taken from eyeballs after 6 hours, serum is separated, and the contents of the cytokines (IFN-gamma and IL-6) in the serum of the mice are detected by adopting an ELISA method. The experimental result is shown in D, E of fig. 8, and the result shows that the content of the cytokines (IFN-gamma and IL-6) of the model group mice is obviously increased compared with that of the blank group; and the test group can obviously inhibit the expression quantity of cytokines (IFN-gamma and IL-6) induced by LPS by administering polypeptide CTP, thereby inhibiting inflammatory reaction.
In conclusion, the hybrid peptide CTP has bidirectional immunoregulation effect. On one hand, CTP can enhance the immunocompetence of the organism in a normal state or an immune function inhibition state, promote the phagocytosis capability of macrophages to foreign matters in the aspect of the innate immunity of the organism, improve the expression level of cytokines and protect the damage of immunosuppression to the organism. Therefore, the polypeptide CTP can be used for preventing and treating infection caused by low immune defense and immune monitoring functions. On the other hand, the polypeptide CTP can inhibit the inflammatory reaction of the organism, reduce the release amount of cytokines in the inflammatory state and relieve the damage of the inflammatory reaction to tissues such as intestinal tracts of animals and human beings. Therefore, the polypeptide CTP can be used for treating inflammatory diseases (such as enteritis and the like).
In addition, the invention also carries out functional experiments on derivatives of the polypeptide CTP, such as the CTP with amidated tail end and the CTP after corresponding substitution of the 6 th amino acid, and the result shows that the derivatives of the polypeptide CTP also have similar immune anti-inflammatory bidirectional regulation function with the polypeptide CTP.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the technical principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> university of agriculture in China
<120> a hybrid polypeptide with immunoregulation and anti-inflammatory function, its preparation method and application
<130> KHP191110423.2
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Arg Trp Gly Arg Phe Leu Arg Lys Ile Lys Arg Arg Glu Arg Pro Lys
1 5 10 15
Arg Lys Asp Val Thr
20
<210> 2
<211> 16
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Arg Trp Gly Arg Phe Leu Arg Lys Ile Lys Arg Arg Glu Arg Pro Lys
1 5 10 15
<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Arg Lys Asp Val Tyr
1 5
<210> 4
<211> 21
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Arg Lys Asp Val Thr Arg Trp Gly Arg Phe Leu Arg Lys Ile Lys Arg
1 5 10 15
Arg Glu Arg Pro Lys
20
<210> 5
<211> 21
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Arg Trp Gly Arg Phe Leu Arg Lys Ile Lys Arg Arg Glu Arg Pro Lys
1 5 10 15
Tyr Val Asp Lys Arg
20
<210> 6
<211> 63
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
agatggggta gattcttgag aaagatcaag agaagagaaa gaccaaagag aaaggacgtt 60
act 63
<210> 7
<211> 96
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
ggtaccagat ggggtagatt cttgagaaag atcaagagaa gagaaagacc aaagagaaag 60
gacgttactc atcatcatca tcatcattga tctaga 96
<210> 8
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
ccagatgggg tagattctt 19
<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
gtaacgtcct ttctctttg 19
Claims (11)
1. A hybrid peptide with immunoregulatory and anti-inflammatory functions is characterized in that the amino acid sequence of the hybrid peptide is shown as SEQ ID NO. 1.
2. A gene encoding the hybrid peptide of claim 1.
3. The gene of claim 2, wherein the nucleotide sequence of the gene is shown as SEQ ID No. 6.
4. Biomaterial containing the genes of claim 2 or 3, characterized in that it is a recombinant DNA, an expression cassette, a transposon, a plasmid vector, a phage vector, a viral vector or a host cell.
5. A method of preparing the hybrid peptide of claim 1, comprising: introducing the gene of claim 2 or 3 into a host cell and expressing the hybrid peptide.
6. The method of claim 5, wherein the host cell is a yeast.
7. The method of claim 6, wherein the yeast is Pichia pastoris.
8. Use of a hybrid peptide according to claim 1 or a hybrid peptide produced by a method according to any one of claims 5 to 7 or a gene according to claim 2 or 3 or a biological material according to claim 4 for the preparation of an immunomodulating formulation.
9. Use of the hybrid peptide of claim 1 or the hybrid peptide produced by the method of any one of claims 5 to 7 or the gene of claim 2 or 3 or the biomaterial of claim 4 for the preparation of an anti-inflammatory agent.
10. Use according to claim 8 or 9, wherein the preparation is a medicament, nutraceutical, food or feed additive.
11. A product comprising a hybrid peptide according to claim 1 or a hybrid peptide produced by a method according to any one of claims 5 to 7;
the product is any one selected from medicine, health product, food or feed additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910265006.4A CN110128544B (en) | 2019-04-03 | 2019-04-03 | Hybrid peptide with immunoregulation and anti-inflammatory functions and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910265006.4A CN110128544B (en) | 2019-04-03 | 2019-04-03 | Hybrid peptide with immunoregulation and anti-inflammatory functions and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110128544A CN110128544A (en) | 2019-08-16 |
| CN110128544B true CN110128544B (en) | 2020-12-01 |
Family
ID=67568991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910265006.4A Active CN110128544B (en) | 2019-04-03 | 2019-04-03 | Hybrid peptide with immunoregulation and anti-inflammatory functions and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110128544B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111848817B (en) * | 2020-07-28 | 2021-11-09 | 中国农业大学 | Multifunctional hybrid peptide with antibacterial, antiviral, immunoregulatory and anti-inflammatory activities, and preparation method and application thereof |
| CN111944058B (en) * | 2020-07-28 | 2021-12-17 | 中国农业大学 | Multifunctional hybrid peptide with antibacterial, anti-inflammatory, endotoxin neutralization and immunoregulation activities, and preparation method and application thereof |
| CN111944060B (en) * | 2020-07-29 | 2022-02-25 | 中国农业大学 | Multifunctional hybrid peptide with antibacterial, anti-inflammatory and detoxifying activities and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225113A (en) * | 2008-01-30 | 2008-07-23 | 山东大学 | Thymosin alpha1-thymopentin fusion peptide and preparation method thereof |
| WO2010093245A1 (en) * | 2009-02-13 | 2010-08-19 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Antimicrobial peptides based on cmap27 |
| WO2015161820A1 (en) * | 2014-04-24 | 2015-10-29 | 中国人民解放军军事医学科学院毒物药物研究所 | Amphiphilic synthetic antimicrobial peptide, and pharmaceutical composition and use thereof |
| CN106488929A (en) * | 2014-05-09 | 2017-03-08 | 乌得勒支大学控股有限公司 | Novel C ATH2 derivant |
| CN107043428A (en) * | 2017-05-02 | 2017-08-15 | 东北农业大学 | A kind of anti-inflammatory heterozygous antibacterial peptide of αhelix and its preparation method and application |
-
2019
- 2019-04-03 CN CN201910265006.4A patent/CN110128544B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225113A (en) * | 2008-01-30 | 2008-07-23 | 山东大学 | Thymosin alpha1-thymopentin fusion peptide and preparation method thereof |
| WO2010093245A1 (en) * | 2009-02-13 | 2010-08-19 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Antimicrobial peptides based on cmap27 |
| WO2015161820A1 (en) * | 2014-04-24 | 2015-10-29 | 中国人民解放军军事医学科学院毒物药物研究所 | Amphiphilic synthetic antimicrobial peptide, and pharmaceutical composition and use thereof |
| CN106232616A (en) * | 2014-04-24 | 2016-12-14 | 中国人民解放军军事医学科学院毒物药物研究所 | Amphipathic synthetic antibacterial peptide, its medical composition and its use |
| CN106488929A (en) * | 2014-05-09 | 2017-03-08 | 乌得勒支大学控股有限公司 | Novel C ATH2 derivant |
| CN107043428A (en) * | 2017-05-02 | 2017-08-15 | 东北农业大学 | A kind of anti-inflammatory heterozygous antibacterial peptide of αhelix and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 杂合抗菌肽设计及生物学活性的研究进展;武如娟，张日俊;《中国生物工程杂志》;20130915;第33卷(第9期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110128544A (en) | 2019-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110128544B (en) | Hybrid peptide with immunoregulation and anti-inflammatory functions and preparation method and application thereof | |
| CN110066342B (en) | Hybrid peptide with functions of immunoregulation, endotoxin neutralization and digestion and anti-inflammation, and preparation method and application thereof | |
| CN110128548B (en) | Hybrid peptide with functions of regulating immunity, resisting oxidation, resisting inflammation and detoxifying, and preparation method and application thereof | |
| AU676891B2 (en) | Pharmaceutical containing the P40 subunit of interleukin 12 | |
| NZ203042A (en) | Increasing milk production in cows by administering synthetic bovine growth hormone | |
| CN113637068B (en) | Recombinant I-type humanized collagen C1L5T and preparation method and application thereof | |
| CN106232616A (en) | Amphipathic synthetic antibacterial peptide, its medical composition and its use | |
| CN102220255A (en) | Recombinant antimicrobial peptide (AMP) as well as genetic engineering preparation method and application thereof | |
| CN113683680A (en) | Recombinant I-type humanized collagen C1L1T, and preparation method and application thereof | |
| CN113683679A (en) | Recombinant I-type humanized collagen C1L6T and preparation method and application thereof | |
| DE60018426T2 (en) | HIGHLY CLEANED CYTOKIN ACTIVATING FACTOR AND METHOD FOR ITS USE | |
| CN110922466B (en) | Bioactive polypeptide KSWNETFHARLA, and preparation method and application thereof | |
| CN110903376A (en) | Bioactive polypeptide RISLPLPTFSSL, and preparation method and application thereof | |
| CN115772228A (en) | Duck interferon fusion protein displayed on yeast surface and application thereof | |
| CN110559424B (en) | Application of outer membrane protein in preparation of malignant tumor immunotherapy medicine | |
| CN112851791A (en) | Novel FGF19 analogue and application thereof | |
| CN111848817B (en) | Multifunctional hybrid peptide with antibacterial, antiviral, immunoregulatory and anti-inflammatory activities, and preparation method and application thereof | |
| CN113683681A (en) | Recombinant I-type humanized collagen C1L3T, and preparation method and application thereof | |
| CN110964094B (en) | Human leukocyte protease inhibitor and its recombinant preparation and application | |
| CN115536738A (en) | Application of cobra antibacterial peptide OH-CATH30 in treating enteritis of fishes | |
| CN114716515A (en) | Polypeptide analogue and preparation method and application thereof | |
| CN111518189A (en) | Antimicrobial peptide MSPiscidin-3, and coding gene and application thereof | |
| CN100535006C (en) | Analog of GLP-1 | |
| US5440022A (en) | Hepatokine and methods for its use | |
| KR20120130916A (en) | The polypeptide derived from sebastes schlegelii and Immune Booster Composition for fish Comprising thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |